Methotrexate toxicity is characterized by nausea, diarrhea, mucocutaneous ulcerations, pancytopenia, or gastrointestinal bleeding (
7-
9). Methotrexate, when given in high doses (> 1 g/m
2), can lead to kidney injury, whereas renal dysfunction can cause methotrexate toxicity due to a decrease in renal clearance (
10-
13). However, mucocutaneous ulceration can be an early clinical sign of imminent systemic toxicity, and isolated mucosal or cutaneous lesions may sometimes be the only presentation seen in 3 - 10% of patients (
14-
16). In the event a patient takes an overdose of methotrexate or takes it before the next scheduled weekly day, the proliferation of escaped cells will not occur, and ultimately, more than requisite cells will get affected, thereby resulting in erosions and ulcerations as a manifestation of methotrexate toxicity (
17). The clue which assists in early recognition is the burning sensation and pain in psoriatic plaques, which is out of proportion to the clinical appearance of lesions (
18,
19).
Methotrexate-induced side effects can be due to dose-dependent or idiosyncratic mechanisms. Incorrect intake of drug and various drug interactions are contributory factors (
8). These drugs include proton-pump inhibitors, trimethoprim/sulfamethoxazole, doxycycline, non-steroidal anti-inflammatory drugs (NSAIDs), and salicylates that decrease protein binding or reduce renal clearance, as well as excessive alcohol consumption can play an important role in Methotrexate toxicity (
17). In our case, incorrect intake of drug was identified as the causative factor, which was different than usual presentations of methotrexate toxicity because of resemblance of lesions with autoimmune vesiculobullous disorders or severe drug reactions like (SJS/TEN); however, histopathology and direct immunofluorescence studies ruled out both differential diagnoses. Although she was a diagnosed case of psoriasis, there was no clinical or histopathological evidence of the same at presentation, which might be attributed to the ulceration of the pre-existing psoriatic lesions.
Withdrawal of methotrexate and administration of intravenous folinic acid (leucovorin) as early as possible after exposure is an essential initial treatment that should not be delayed at any cost (
2). Supportive treatment with IV fluids, IV antacids, IV antibiotics, antibiotic-impregnated gauzes for erosions, oral care, colony-stimulating factor (filgrastim) if severe neutropenia, urine alkalization with bicarbonate infusion (if indicated) should be started simultaneously. Improvement in clinical manifestations can occur as early as ten days after discontinuation of methotrexate (
7). The patient should be carefully monitored for vital signs, as well as any signs of infections or bleeding and abnormalities in laboratory parameters to assess renal and hepatic function.